MELANOMASEQPlus : 1015610

Please provide most recent Pathology report.

Test Code
MDFCPNGSMEL or 1015610

CPT Codes

MELANOMASEQPlus panel components: BRAF, KRAS, HRAS, NRAS, KIT, GNA11, GNAQ, GNAS, PIK3CA, PTEN, CTNNB1 med fusion can deliver your SEQ report by fax or eLabs Results Portal. Please contact your med fusion representative to make them aware of your desired delivery and if you need access to the results portal. The results portal will provide links for additional therapy and clinical trial information associated with the patient’s molecular profile. If you have any further questions, additional needs, or would like to speak with med fusion’s scientific staff, pathologists, or client services, please contact us at 972-966-7050/844-966-7050.

Tissue, Core Needle Biopsy (4-6 aspirates, 18 gauge needle preferred), Fine Needle Aspirate (FNA), or Malignant fluid in formalin fixed paraffin embedded block (FFPE). Tissue slides may be submitted.

Transport Container
Paraffin embedded Tissue: submit in sterile biohazard plastic bag. Slides: Unstained, positively charged, unbaked 5 micron sections; submit 10 FFPE in slide holder. Specimen to be tested must contain a minimum of 20 percent tumor.

Transport Temperature
Paraffin embedded Tissue: Ambient or on ice pack in summer; Slides: Ambient.

Specimen Stability
Paraffin embedded tissue: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Decalcified tissue specimen.

Next Generation Sequencing

Setup Schedule

Report Available
8-10 days

Laboratory test results should always be considered in the context of clinical observations. This test was developed and its performance characteristics determined by med fusion. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.

Reference Range
An interpretive report will be provided.

Clinical Significance
Disease-specific solid tumor panel intended to aid the oncologist in prioritizing standard of care therapy and clinical trial choices for patients with advanced stage melanoma.

Performing Laboratory
med fusion

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.